Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists mine 1,100 patient records to spot thyroid cancer return risks

NCT ID NCT07695974

Knowledge-focused Sponsor: University of Roma La Sapienza Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study examines medical records from over 1,100 adults who had papillary thyroid cancer and were declared cancer-free after initial treatment. Researchers want to identify which patient characteristics—such as age, tumor size, or cancer spread—are linked to a higher chance of the cancer coming back. No new treatments or tests are given; the team simply reviews existing data to find patterns that could improve follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better identify which thyroid cancer patients need closer monitoring after treatment.
What could go wrong
This is an observational study that looks back at past data, so it cannot prove cause and effect. The findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,113 people

The number who actually took part.

Started

Jan 2000

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of adult patients treated for histologically confirmed papillary thyroid carcinoma at the Department of Surgery of Sapienza University of Rome, Policlinico Umberto I Hospital, between 2000 and 2018. Patients were identified from a prospectively maintained institutional database and had undergone primary surgical treatment and subsequent postoperative surveillance at the same tertiary referral center.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * histologically confirmed diagnosis of papillary thyroid carcinoma * no history of previous neck surgery * availability of complete clinical, pathological, treatment, and follow-up data; * achievement of an initial disease-free status after primary treatment * minimum follow-up of 60 months for patients who remained recurrence-free Exclusion Criteria: * histological diagnosis other than papillary thyroid carcinoma * previous neck surgery * incomplete clinical, pathological, treatment, or follow-up records * follow-up shorter than 60 months in patients without recurrence * biochemical or structural evidence of persistent disease after initial treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Papillary thyroid carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Thyroid Cancer, Papillary thyroid gland papillary carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Papillary thyroid carcinoma Recurrence free survival

Contacts and locations

Locations

  • Sapienza University of Rome - Policlinico Umberto I Hospital

    Roma, 00161, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.